WO2000019999A1 - Fulvic acid and its use in the treatment of various conditions - Google Patents
Fulvic acid and its use in the treatment of various conditions Download PDFInfo
- Publication number
- WO2000019999A1 WO2000019999A1 PCT/IB1999/001649 IB9901649W WO0019999A1 WO 2000019999 A1 WO2000019999 A1 WO 2000019999A1 IB 9901649 W IB9901649 W IB 9901649W WO 0019999 A1 WO0019999 A1 WO 0019999A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- derivative
- salt
- ester
- acid
- fulvic acid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- This invention relates to fulvic acid and its use in the treatment of various conditions.
- Humic substances are ubiquitous in nature and arise from the decay of plant and animal residues in the environment (MacCarthe et al. 1990). These substances can be divided into humic acid, fulvic acid and humin on the basis of the solubility in water as a function of pH. Fulvic acid is the fraction that is soluble in water under all pH conditions and is in general lower in molecular size and weight and lower in colour intensity than humic acids.
- Humic substances commonly account for 50% of the dissolved organic carbon concentrations in stream water, of which 90 to 95 % are fulvic acids. Humic acids are 3 to 5 times more abundant in soils than fulvic acids (Stevenson, 1982), whereas fulvic acids are 9 to 10 times more abundant in water than humic acids (Malcolm, 1985).
- Humic acids have been successfully used in the treatment of:
- a pharmaceutical composition comprising a fulvic acid, salt, ester or derivative thereof as the active ingredient.
- the pharmaceutical composition may be provided for oral or topical administration to a subject.
- composition may be provided in the form of a solution, paste, ointment, powder or any other form suitable for topical administration.
- the subject may be a human or an animal.
- a fulvic acid, salt, ester or derivative thereof in the treatment of a condition of a subject.
- the condition may, for example, be inflammation, acne, eczema or bacterial or fungal or viral infections.
- the treatment of the condition may be by oral or topical administration.
- the subject is typically a human or an animal.
- the fulvic acid is preferably a fulvic acid derived from a wet coal oxidation process of the type described in US patent 4,912,256. Such a fulvic acid is hereinafter referred to as "oxifulvic acid or OFA" .
- Phenolic groups 2,3 - 3,7 meq/g
- a composition for topical application to a human or animal comprises 4,5 percent, or 9,0 percent, by mass of oxifulvic acid in an aqueous cream.
- Figures 1 to 4 illustrate graphically the results of certain tests carried out on oxifulvic acid
- Figures 5A and 5B illustrate photographically the results of treating pyotraumatic dermatitis using an oxifulvic acid cream of the invention.
- the active ingredient in the practice of the invention is a fulvic acid, salt, ester or derivative thereof.
- Oxifulvic acid having the preferred functional group analysis mentioned above, has been subjected to a number of in vitro and in vivo studies and these are described hereinafter.
- the superoxide scavenging activities of oxifulvic acid were determined using the hypoxanthine (lmM)/xanthine-oxidase (lOOmU/ml) enzymatic system to generate superoxide.
- Oxifulvic acid exhibited superoxide-scavenging activity (Table 2).
- IL-2 inter leukin 2
- PHA phytohemaglutinin
- Oxifulvic acid caused a statistically significant decrease in IL-2 production by stimulated lymphocytes at all three concentrations tested ( Figure 2).
- mice 2,4-dinitro-l- fluorobenzene (DNFB) sensitized mice were evaluated using 50 BALB C female mice (6-7 weeks old) according to the method described by Rheins et al (1987).
- the mice were sensitized by application of DNFB to the shaved abdomen, divided into 5 groups and challenged on the right ear 6 days later.
- the inflamed ears of the mice in each group were treated topically for two days with one of the following creams i.e. control cream, oxifulvic acid 4.5%, oxifulvic acid 9%, dichlophenac sodium 1% (Voltaren Emulgel ® ) and betamethasone 0.1 % (Betnovate ® ).
- the thickness of the ear was measured with a clock gauge before the challenge and 24 and 48h later.
- Biopsies of control lesions (prior to treatment) of approximately 3 mm were collected, fixed in formalin and followed up with biopsies as close as possible to the site of the previous biopsy following treatment.
- the formalin-fixed skin-biopsies were processed according to standard routine methods used for histological studies, embedded in paraffin-wax and slices of 6 ⁇ m each were prepared. All slices were coloured using the Haemotoxillin and Eosine staining method.
- the histopathological findings are shown in Table 4.
- the control samples were initially investigated for specific morphological lesions which were graded as indicated in Table 4.
- the biopsies of the treated lesions were evaluated similarly.
- the surface (shallow) exudative dermatitis did show accelerated healing in all cases.
- Hyperplastic epidermis acantosis
- the degree of dermal inflammation was also reduced in all except one of the treated lesions when compared to the original untreated lesions.
- the data shows that none of the products produced any measurable toxicity during the acute dermal or oral exposure tests.
- oxifulvic acid exhibits some measure of antimicrobial activity or bacteriostatic or fungistatic efficacy against some of the test organisms, even when formulated in a cream.
- the 4,5 percent oxifulvic acid cream was subjected to a preservative efficacy test by the Microbiological Division of the SABS and it was found that the cream complied with the requirements of the USP 23 (1995).
- Viruses were grown in either vervet monkey kidney cells or a primary liver cancer cell line (PLC/PRF/5). Stock virus suspensions were titrated to establish their titre and to prepare a viral suspension containing 100 X 50% tissue culture infectious dose (100TCID 50 )/200 ⁇ l.
- Inhibition of viral replication in the host cell Monolayers of the appropriate cell cultures in 96-well microtitre trays were washed and starved for a minimum of 1 hr in serum-free MEM. After starvation 100TCID 50 virus was added to all wells and allowed to adsorb for l-2hrs. After adsorption, the unadsorbed viruses were washed from the wells using serum-free MEM. Thereafter doubling dilutions of oxifulvic acid, in serum-free MEM, were added to the appropriate wells. The microtitre trays were incubated at 37°C and examined daily, for 7 days, for CPE. Wells inoculated with 100TCID 50 viruses and no oxifulvic acid acted as positive controls. The appearance of CPE indicated that no inhibition of viral replication had taken place.
- Oxifulvic acid is therefore a compound that
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU59923/99A AU766198B2 (en) | 1998-10-08 | 1999-10-08 | Fulvic acid and its use in the treatment of various conditions |
JP2000573359A JP4700808B2 (en) | 1998-10-08 | 1999-10-08 | Fulvic acid and its use in the treatment of various conditions |
US09/807,004 US6569900B1 (en) | 1998-10-08 | 1999-10-08 | Fulvic acid and its use in the treatment of various conditions |
EP99970022A EP1126837B1 (en) | 1998-10-08 | 1999-10-08 | Fulvic acid and its use in the treatment of various conditions |
DE69932939T DE69932939T2 (en) | 1998-10-08 | 1999-10-08 | FULVIC ACID AND ITS USE FOR THE TREATMENT OF VARIOUS DISEASE STATES |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ZA98/9190 | 1998-10-08 | ||
ZA989190 | 1998-10-08 | ||
ZA99/2848 | 1999-04-21 | ||
ZA992848 | 1999-04-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000019999A1 true WO2000019999A1 (en) | 2000-04-13 |
Family
ID=27144980
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB1999/001649 WO2000019999A1 (en) | 1998-10-08 | 1999-10-08 | Fulvic acid and its use in the treatment of various conditions |
Country Status (7)
Country | Link |
---|---|
US (1) | US6569900B1 (en) |
EP (4) | EP1700599B1 (en) |
JP (1) | JP4700808B2 (en) |
AT (4) | ATE336997T1 (en) |
AU (1) | AU766198B2 (en) |
DE (4) | DE69939722D1 (en) |
WO (1) | WO2000019999A1 (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006064449A1 (en) * | 2004-12-15 | 2006-06-22 | Van Der Westhuizen Cornelis Fl | Detoxifying and immunity-booster composition |
WO2007125492A2 (en) * | 2006-05-02 | 2007-11-08 | Pfeinsmith S.A. (Pty) Ltd | Acidic composition |
WO2010082182A1 (en) | 2009-01-19 | 2010-07-22 | Natracine Limited | Fulvic acid in combination with fluconazole or amphotericin b for the treatment of fungal infections |
WO2011023970A1 (en) | 2009-08-27 | 2011-03-03 | Natracine Uk Limited | Fulvic acid compositions and their use |
WO2013132444A1 (en) | 2012-03-07 | 2013-09-12 | Natracine Uk Limited | Fulvic acid and antibiotic combination for the inhibition or treatment of multi-drug resistant bacteria |
WO2017102565A1 (en) * | 2015-12-15 | 2017-06-22 | Rita Dobmeyer | Pharmaceutical composition comprising a fulvic acid and at least one boron-containing compound |
WO2017146792A1 (en) * | 2016-02-26 | 2017-08-31 | Omni Bioceutical Innovations, Inc. | Compositions of bioactive fulvate fractions and uses thereof |
WO2020187803A1 (en) * | 2019-03-20 | 2020-09-24 | Rita Dobmeyer | Pharmaceutical composition |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1797190B1 (en) * | 2004-06-23 | 2010-10-27 | Lone Knight Limited | Method for extracting fulvic acid molecules |
US20080160111A1 (en) * | 2005-02-28 | 2008-07-03 | Hiroko Isoda | Type I Allergy Inhibitor and Methods of Inhibiting the Onset of Type I Allergy Using Fulvic Acid |
JP2006232785A (en) * | 2005-02-28 | 2006-09-07 | Univ Of Tsukuba | Type i allergy inhibitor using fulvic acid and method for inhibiting onset of type i allergy |
US20070212434A1 (en) * | 2006-03-07 | 2007-09-13 | Day Kenneth S | Compositions and methods for human use containing fulvic acid |
BRPI0913586A8 (en) * | 2008-06-05 | 2018-03-13 | Pfeinsmith Ltd | combination, and use of a combination. |
DE102008058552A1 (en) | 2008-11-21 | 2010-05-27 | Mankau, Dieter, Prof. Dr. | Spring frame and spring body for supporting z. B. a mattress |
WO2013023062A1 (en) * | 2011-08-09 | 2013-02-14 | Wilford Lynn C | Antimicrobial agents and methods for use thereof in the abatement of food borne pathogenic organisms |
US9932319B2 (en) | 2013-05-28 | 2018-04-03 | Empire Technology Development Llc | Antioxidant humic acid derivatives and methods of preparation and use |
CN105246879A (en) | 2013-05-28 | 2016-01-13 | 英派尔科技开发有限公司 | Humic acid derivatives and methods of preparation and use |
CN105555314B (en) | 2013-06-28 | 2019-02-26 | 英派尔科技开发有限公司 | Edible plasticizer for food and food package film |
JP6120342B1 (en) * | 2016-03-08 | 2017-04-26 | 株式会社スタイルアンドバリュージャパン | Beauty composition |
EP3799854A1 (en) | 2019-10-01 | 2021-04-07 | Stefan Johannes Fellner | Extract of organic humified materials |
KR102258006B1 (en) * | 2020-12-22 | 2021-05-28 | 허교 | Antiviral composition containing fulvic acid as an active ingredient |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2850685A1 (en) * | 1978-11-22 | 1980-06-04 | Kneer Franz X | Colloidal mud bath or paste material prodn. - by composting mixt. of clarified sludge and natural carbon source |
GB2244215A (en) * | 1990-05-25 | 1991-11-27 | Nat Energy Council | Bacteriostatic and bactericidal composition |
JPH0687752A (en) * | 1992-09-04 | 1994-03-29 | Kyowa Kagaku Kogyo Kk | Antimicrobial water and its production |
CN1097990A (en) * | 1994-01-29 | 1995-02-01 | 康宏盛 | A kind of medicine for the treatment of tinea cruris |
WO1997049288A1 (en) * | 1996-06-27 | 1997-12-31 | Organocure (Proprietary) Limited | Method of treating a plant disease |
JPH119674A (en) * | 1997-06-25 | 1999-01-19 | M S K Planning:Kk | Liquid deodorizier with humic acid as effective component, its production beverage deodorizer with humic acid as effective component and its production |
CN1213665A (en) * | 1998-08-25 | 1999-04-14 | 祝亚勤 | Prepn. method of medicinal-grade peat sodium fulvic acid |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB244215A (en) | 1924-10-09 | 1925-12-17 | Richard William Bailey | Improvements in or relating to gas or oil power plant |
JPH0466508A (en) * | 1990-07-03 | 1992-03-02 | Suntory Ltd | Fungicidal agent |
JPH1017483A (en) * | 1996-06-26 | 1998-01-20 | Keinzu Corp:Kk | Preventing and therapeutic agent for dermatopathy |
-
1999
- 1999-10-08 EP EP06012244A patent/EP1700599B1/en not_active Expired - Lifetime
- 1999-10-08 DE DE69939722T patent/DE69939722D1/en not_active Expired - Lifetime
- 1999-10-08 AT AT99970022T patent/ATE336997T1/en not_active IP Right Cessation
- 1999-10-08 WO PCT/IB1999/001649 patent/WO2000019999A1/en active IP Right Grant
- 1999-10-08 AT AT06012243T patent/ATE410158T1/en not_active IP Right Cessation
- 1999-10-08 AT AT06012244T patent/ATE410159T1/en not_active IP Right Cessation
- 1999-10-08 AT AT06012245T patent/ATE410160T1/en not_active IP Right Cessation
- 1999-10-08 JP JP2000573359A patent/JP4700808B2/en not_active Expired - Fee Related
- 1999-10-08 EP EP06012245A patent/EP1700600B1/en not_active Expired - Lifetime
- 1999-10-08 EP EP99970022A patent/EP1126837B1/en not_active Expired - Lifetime
- 1999-10-08 US US09/807,004 patent/US6569900B1/en not_active Expired - Lifetime
- 1999-10-08 DE DE69939721T patent/DE69939721D1/en not_active Expired - Lifetime
- 1999-10-08 DE DE69939720T patent/DE69939720D1/en not_active Expired - Lifetime
- 1999-10-08 DE DE69932939T patent/DE69932939T2/en not_active Expired - Lifetime
- 1999-10-08 EP EP06012243A patent/EP1698333B1/en not_active Expired - Lifetime
- 1999-10-08 AU AU59923/99A patent/AU766198B2/en not_active Ceased
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2850685A1 (en) * | 1978-11-22 | 1980-06-04 | Kneer Franz X | Colloidal mud bath or paste material prodn. - by composting mixt. of clarified sludge and natural carbon source |
GB2244215A (en) * | 1990-05-25 | 1991-11-27 | Nat Energy Council | Bacteriostatic and bactericidal composition |
JPH0687752A (en) * | 1992-09-04 | 1994-03-29 | Kyowa Kagaku Kogyo Kk | Antimicrobial water and its production |
CN1097990A (en) * | 1994-01-29 | 1995-02-01 | 康宏盛 | A kind of medicine for the treatment of tinea cruris |
WO1997049288A1 (en) * | 1996-06-27 | 1997-12-31 | Organocure (Proprietary) Limited | Method of treating a plant disease |
JPH119674A (en) * | 1997-06-25 | 1999-01-19 | M S K Planning:Kk | Liquid deodorizier with humic acid as effective component, its production beverage deodorizer with humic acid as effective component and its production |
CN1213665A (en) * | 1998-08-25 | 1999-04-14 | 祝亚勤 | Prepn. method of medicinal-grade peat sodium fulvic acid |
Non-Patent Citations (4)
Title |
---|
DATABASE EPODOC EUROOPEAN PATENT OFFICE; 14 April 1999 (1999-04-14), ZHU YAUIN: "Prepn. of medcinal-grade peat soldium fulvic acid", XP002127437 * |
DATABASE WPI Section Ch Week 199417, Derwent World Patents Index; Class B04, AN 1994-140953, XP002127438 * |
DATABASE WPI Section Ch Week 199721, Derwent World Patents Index; Class B05, AN 1997-226868, XP002127439 * |
DATABASE WPI Section Ch Week 199913, Derwent World Patents Index; Class D13, AN 1999-146250, XP002127440 * |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006064449A1 (en) * | 2004-12-15 | 2006-06-22 | Van Der Westhuizen Cornelis Fl | Detoxifying and immunity-booster composition |
WO2007125492A2 (en) * | 2006-05-02 | 2007-11-08 | Pfeinsmith S.A. (Pty) Ltd | Acidic composition |
WO2007125492A3 (en) * | 2006-05-02 | 2008-01-10 | Pfeinsmith S A Pty Ltd | Acidic composition |
US8114910B2 (en) | 2006-05-02 | 2012-02-14 | Pfeinsmith S.A. (Pty) Ltd. | Acidic composition |
WO2010082182A1 (en) | 2009-01-19 | 2010-07-22 | Natracine Limited | Fulvic acid in combination with fluconazole or amphotericin b for the treatment of fungal infections |
WO2011023970A1 (en) | 2009-08-27 | 2011-03-03 | Natracine Uk Limited | Fulvic acid compositions and their use |
WO2013132444A1 (en) | 2012-03-07 | 2013-09-12 | Natracine Uk Limited | Fulvic acid and antibiotic combination for the inhibition or treatment of multi-drug resistant bacteria |
WO2017102565A1 (en) * | 2015-12-15 | 2017-06-22 | Rita Dobmeyer | Pharmaceutical composition comprising a fulvic acid and at least one boron-containing compound |
WO2017146792A1 (en) * | 2016-02-26 | 2017-08-31 | Omni Bioceutical Innovations, Inc. | Compositions of bioactive fulvate fractions and uses thereof |
US9820953B2 (en) | 2016-02-26 | 2017-11-21 | Omni Bioceutical Innovations, Inc. | Compositions of bioactive fulvate fractions and uses thereof |
US11376231B2 (en) | 2016-02-26 | 2022-07-05 | Omni Bioceutical Innovations, Inc. | Compositions of bioactive fulvate fractions and uses thereof |
WO2020187803A1 (en) * | 2019-03-20 | 2020-09-24 | Rita Dobmeyer | Pharmaceutical composition |
Also Published As
Publication number | Publication date |
---|---|
EP1700600B1 (en) | 2008-10-08 |
JP2002526407A (en) | 2002-08-20 |
EP1698333B1 (en) | 2008-10-08 |
AU766198B2 (en) | 2003-10-09 |
DE69939722D1 (en) | 2008-11-20 |
EP1700600A1 (en) | 2006-09-13 |
DE69932939D1 (en) | 2006-10-05 |
AU5992399A (en) | 2000-04-26 |
ATE410158T1 (en) | 2008-10-15 |
EP1126837A1 (en) | 2001-08-29 |
ATE336997T1 (en) | 2006-09-15 |
JP4700808B2 (en) | 2011-06-15 |
DE69939721D1 (en) | 2008-11-20 |
DE69932939T2 (en) | 2006-12-07 |
EP1700599A1 (en) | 2006-09-13 |
EP1698333A1 (en) | 2006-09-06 |
ATE410159T1 (en) | 2008-10-15 |
US6569900B1 (en) | 2003-05-27 |
DE69939720D1 (en) | 2008-11-20 |
EP1126837B1 (en) | 2006-08-23 |
ATE410160T1 (en) | 2008-10-15 |
EP1700599B1 (en) | 2008-10-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2000019999A1 (en) | Fulvic acid and its use in the treatment of various conditions | |
US6709681B2 (en) | Acidified nitrite as an antimicrobial agent | |
DE69532469T2 (en) | Adhesion-inhibiting vaccine extract | |
US4503037A (en) | Composition for the treatment of epithelial injuries and process for the preparation thereof | |
CA1050548A (en) | Zinc sulfadiazine as a medicament | |
Nwankpa et al. | Phyto-nutrient composition and antioxidative potential of ethanolic leaf extract of Sida acuta in wistar albino rats | |
IE60403B1 (en) | Pharmaceutical use of graminaceous extracts | |
US4256743A (en) | Inhibition of bone resorption with H1 -blocking antihistamines | |
DE69918781T2 (en) | THE USE OF TEE POLYPHENOLES FOR THE PREPARATION OF ANTI-CHLAMYDIA AGENTS | |
JPH0665085A (en) | Tyrosinase activity inhibitor | |
US5260067A (en) | Cytotropic heterogeneous molecular lipids (CHML) and process for preparing the same | |
JPH03255033A (en) | Treating agent for trichophyton | |
JP3273812B2 (en) | Cosmetics | |
DE60128801T2 (en) | Isoflavones against radiation-induced mortality | |
JP3235922B2 (en) | Cosmetics | |
JPS61500067A (en) | 1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid or its metal salt and sulfur | |
EP0348507A1 (en) | Pharmaceutical preparation for individual prophylaxis of venereal diseases and curing urogenital trichomoniasis | |
EP3463393A1 (en) | A composition comprising a mixture of an extract and bentonite | |
JP2001322990A (en) | Active oxygen scavenger and composition containing the same for erasing active oxygen | |
ZA200102419B (en) | Fulvic acid and its use in the treatment of various conditions. | |
JP2000256196A (en) | Anti-inflammatory and anti-allergic medicine | |
JPH1036278A (en) | Agent for suppressing formation of lipid peroxide and composition containing the agent | |
NZ205587A (en) | Composition comprising undecylenic acid for treating herpes simplex i | |
JP3167777B2 (en) | Antiviral, antibacterial and bactericide | |
JPH06199694A (en) | Agent for stabilizing blood pressure |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 59923/99 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200102419 Country of ref document: ZA |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2000 573359 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999970022 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09807004 Country of ref document: US |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1999970022 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 59923/99 Country of ref document: AU |
|
WWG | Wipo information: grant in national office |
Ref document number: 1999970022 Country of ref document: EP |